|
Oct 9
|
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
|
|
Oct 7
|
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
|
|
Jul 29
|
Can-Fite Provides Namodenoson Patent Update
|
|
Jun 24
|
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
|
|
Jun 5
|
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
|
|
Apr 25
|
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
|
|
Jan 30
|
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
|
|
Jan 29
|
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
|
|
Dec 20
|
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
|
|
Dec 18
|
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
|
|
Dec 4
|
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
|
|
Nov 30
|
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
|
|
Aug 24
|
Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
|
|
Apr 24
|
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
|